Document is current
Any future updates will be listed below
-
Authors
Mevius, Antje https://orcid.org/0000-0002-9556-6693
Karl, Florian
Wacker, Margarethe
Welte, Robert
Krenzer, Stefanie
Link, Theresa
Maywald, Ulf
Wilke, Thomas
-
Funding
Funding for this research was provided by:
GSK
- License Information
-
More Information
Article History
Received: 18 March 2022
Accepted: 30 June 2022
First Online: 16 July 2022
Declarations
:
: Antje Mevius participated in this study as an employee of IPAM and has nothing to disclose. Florian Karl, Robert Welte, Margarethe Wacker, and Stefanie Krenzer are employees of GSK. Theresa Link reports personal fees from GSK for this work, consulting fees from MSD, personal fees from Novartis, Pfizer, Amgen, Roche, Clovis, MSD, Lilly, GSK, gets support for travel costs from MSD, Celgene, Clovis, Daiichi Sankyo, Pfizer, and reports participation on an Advisory Board from Roche, Tesaro, Amgen, MSD, Pfizer, Lilly, Myriad, Esai, GSK, Gilead. Ulf Maywald is an employee of AOK PLUS. Thomas Wilke is the director of IPAM and works as an advisor for several pharmaceutical/consultancy companies.
: Due to the anonymized retrospective nature of the data, ethical approval of the study was not necessary.
: All authors were involved at each stage of manuscript preparation and approved the final manuscript.
